A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel
Novartis Pharmaceuticals
160 participants
Mar 15, 2026
OBSERVATIONAL
Conditions
Summary
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
Eligibility
Inclusion Criteria2
- Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).
- Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.
Exclusion Criteria1
- Patients Aged <2 Years (24 Months) at Index Date.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07517250